BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$368.42 USD
+10.23 (2.86%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $367.63 -0.79 (-0.21%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$368.42 USD
+10.23 (2.86%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $367.63 -0.79 (-0.21%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Zacks News
Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition
by Zacks Equity Research
Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.
Waters (WAT) Boosts Waters Operating Segment With HPLC System
by Zacks Equity Research
Waters (WAT) launches Alliance iS Bio HPLC system to improve efficiency across biopharma QC laboratories, boosting its Waters Operating segment.
Why Is Perrigo (PRGO) Up 19.1% Since Last Earnings Report?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Green Thumb Industries Inc. (GTBIF) Soars 11.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Green Thumb Industries Inc. (GTBIF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Bio-Rad (BIO) Suffers due to BioPharma Softness, Stiff Competition
by Zacks Equity Research
Bio-Rad's (BIO) margin performance gets affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.
Bio-Rad (BIO) Q4 Earnings Beat, Revenues Miss, Margins Down
by Zacks Equity Research
Bio-Rad (BIO) continues to experience weak demand for Life Science products in China.
Bio-Rad Laboratories (BIO) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 5.80% and 0.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits?
by Zacks Equity Research
Ongoing weakness in the biopharma end markets, impacting the sales of Life Science tools and bioprocessing products, are likely to have impeded Bio-Rad's (BIO) Q4 revenues.
3 Discounted MedTech Stocks Poised for Sturdy Growth in 2024
by Riya Anand
Prestige Consumer Health (PBH), Quest Diagnostics (DGX) and Hologic (HOLX) are currently at discounted zone that are expected to provide long-term gains.
Bio-Rad (BIO) Faces Soft Industry-wide Demand, Macro Woes
by Zacks Equity Research
Bio-Rad's (BIO) margin performance suffers due to elevated raw material costs, increased logistics costs and higher employee-related expenses.
Why Is Phibro (PAHC) Up 13.6% Since Last Earnings Report?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Zimmer (ZBH) Up 10.8% Since Last Earnings Report?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Implied Volatility Surging for On Bio-Rad Laboratories (BIO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Bio-Rad Laboratories (BIO) stock based on the movements in the options market lately.
Bio-Rad (BIO) Hurt by Macroeconomic Woes, Margin Pressure
by Zacks Equity Research
Bio-Rad's (BIO) margin performance is affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.
Bio-Rad (BIO) Misses Q3 Earnings Estimates, Cuts 2023 View
by Zacks Equity Research
The deterioration in biopharma and early biotech customer spending and a challenging macroeconomic environment in China impact Bio-Rad's (BIO) Q3 performance.
Bio-Rad Laboratories (BIO) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of -18.82% and 8.47%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q3 Earnings Due on Oct 26: BSX, BIO & More
by Urmimala Biswas
Medical Device companies' third-quarter results are likely to reflect a year-over-year decline. Let's see how BSX, BIO, EW and LH fare this time.
Bio-Rad Laboratories (BIO) to Post Q3 Earnings: What Awaits?
by Zacks Equity Research
Bio-Rad (BIO) Life Science segment will likely have witnessed growth in Q3, driven by Droplet Digital PCR and qPCR products.
Bio-Rad Laboratories (BIO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Bio-Rad (BIO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Bio-Rad (BIO) stock based on the movements in the options market lately.
ResMed (RMD) Stock Jumps 3.8%: Will It Continue to Soar?
by Zacks Equity Research
ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
New Strong Sell Stocks for September 19th
by Zacks Equity Research
BIO, LPG and COLB have been added to the Zacks Rank #5 (Strong Sell) List on September 19, 2023.
New Strong Sell Stocks for August 18th
by Zacks Equity Research
BIO, REFI and GPK have been added to the Zacks Rank #5 (Strong Sell) List on August 18, 2023.
New Strong Sell Stocks for August 9th
by Zacks Equity Research
BWA, ARR and BIO have been added to the Zacks Rank #5 (Strong Sell) List on August 9, 2023.
Bio-Rad (BIO) Beats on Q2 Earnings Estimates, Cuts 2023 View
by Zacks Equity Research
Growth across the Life Science portfolio and strong double-digit growth for ddPCR drive Bio-Rad (BIO) Q2 performance.